Table 1. Clinical Charateristics of Patients With Breast Cancer (BC) or Ovarian Cancer (OV) and In-Laboratory Controlsa.
| Charateristic | Patients, No. (%) | ||
|---|---|---|---|
| With BC (n = 9639) | With OV (n = 2051) | Controls (n = 3988) | |
| Race/ethnicity | |||
| White | 7208 (74.8) | 1718 (83.8) | 2765 (69.3) |
| African American | 985 (10.2) | 80 (3.9) | 323 (8.1) |
| Hispanic | 874 (9.1) | 161 (7.8) | 561 (14.1) |
| Asian | 572 (5.9) | 92 (4.5) | 339 (8.5) |
| Age at diagnosis, y | |||
| Mean (SD) | 48.7 (11.5) | 55.7 (14.1) | 39.7 (14.7)b |
| ≤45 | 3960 (41.1) | 445 (21.7) | 2671 (67.0) |
| 46-60 | 3876 (40.2) | 768 (37.4) | 951 (23.8) |
| >60 | 1518 (15.7) | 751 (36.6) | 332 (8.3) |
| Not providedc | 285 (3.0) | 87 (4.2) | 34 (0.9) |
| Sex | |||
| Male | 123 (1.3) | 0 | 1315 (33.0) |
| Female | 9516 (98.7) | 2051 (100.0) | 2673 (67.0) |
| BC histology | |||
| IDC | 6829 (70.8) | NA | NA |
| ILC | 493 (5.1) | NA | NA |
| IDC and ILC | 141 (1.5) | NA | NA |
| Not providedc | 2176 (22.6) | NA | NA |
| Bilateral BC | |||
| Yes | 1321 (13.7) | NA | NA |
| Not providedc | 8318 (86.3) | NA | NA |
| BC subtypes (receptor status) | |||
| ER+, PR+, and HER2− (HR+) | 2476 (25.7) | NA | NA |
| ER−, PR−, and HER2+ (HR−) | 278 (2.9) | NA | NA |
| ER+, PR+, and HER2+ (TPBC) | 539 (5.6) | NA | NA |
| ER−, PR−, and HER2− (TNBC) | 1154 (12.0) | NA | NA |
| Additional cancer primary | |||
| Colorectal cancer | 166 (1.7) | 35 (1.7) | NA |
| Uterine cancer | 378 (3.9) | 145 (7.1) | NA |
| Others | 97 (1.0) | 28 (1.4) | NA |
| None | 8998 (93.3) | 1843 (89.8) | NA |
| 1st- or 2nd-Degree relative with any cancer | |||
| Yes | 8152 (84.6) | 1670 (81.4) | NA |
| No | 282 (2.9) | 72 (3.5) | NA |
| Not providedc | 1205 (12.5) | 309 (15.1) | NA |
| 1st- or 2nd-Degree relative with BC | |||
| Yes | 5404 (56.1) | 787 (38.4) | NA |
| No | 3030 (31.4) | 955 (46.6) | NA |
| Not providedc | 1205 (12.5) | 309 (15.1) | NA |
| 1st- or 2nd-Degree relative with OV | |||
| Yes | 981 (10.2) | 245 (11.9) | NA |
| No | 7453 (77.3) | 1497 (73.0) | NA |
| Not providedc | 1205 (12.5) | 309 (15.1) | NA |
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; PR, progesterone receptor; NA, not applicable; TNBC, triple-negative BC; TPBC, triple-positive BC; +, positive for the receptor; −, negative for the receptor.
a
Inferred ethnicity using principal component analysis to identify population substructure based on exome-sequencing data.
b
Age at testing for controls.
c
Incomplete or unavailable clinical information.